Accessibility Menu
Coya Therapeutics logo

Coya Therapeutics(NASDAQ) COYA

Market Cap$107.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)+0%
5 YearN/A
1 Year-28%
1 Month-20%
$4.70
+2.62%
+0.12Today
Coya Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 4.582026-08-06
Coya Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+12.25%USD 4.082026-07-30
1 month-20.35%USD 5.752026-07-07
3 month+11.44%USD 4.112026-05-08
Year to date-21.03%USD 5.802025-12-31
1 year-28.44%USD 6.402025-08-06
3 year+18.96%USD 3.852023-08-07
Since inception+0.22%USD 4.572022-12-29

Coya Therapeutics Financials at a Glance

Market Cap

$107.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$7.94M

Net Income (TTM)

-$21.13M

EPS (TTM)

-$1.08

P/E Ratio

-4.23

Dividend

$0.00

Beta (Volatility)

1.26 (Average)

Price

$4.70

Volume

56,979.078

Open

$4.71

Previous Close

$4.58

Daily Range

$4.65 - $4.83

52-Week Range

$3.71 - $7.75

Estimated Earnings Date

Aug 11, 2026

COYA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Coya Therapeutics

Coya develops medicines for people with diseases like ALS and dementia. Its treatments aim to help the body control harmful immune responses. These therapies target patients with neurodegenerative and autoimmune conditions.

Lab Bench to Bedside: Coya’s Main Offerings

  • Treg-enhancing biologics: Medicines designed to boost regulatory T cells, which help control immune system activity. (100% of revenue from collaboration, not product sales)
  • Treg-derived exosomes: Tiny particles from T cells, being studied for treating brain and immune diseases. (No direct sales revenue)
  • Autologous Treg cell therapy: Uses a patient’s own cells to restore immune balance, mainly for ALS. (No direct sales revenue)
  • Combination biologics: Mixes of immune-boosting proteins for diseases like ALS and dementia. (All revenue from collaboration agreements)

Growth Spurts and Strategic Moves

  • Formed a key partnership with Dr. Reddy's Laboratories in 2024 for ALS drug development.
  • Launched Phase 2 clinical trial for lead drug COYA 302 in ALS in December 2025.
  • Expanded pipeline with new drug candidates COYA 303, COYA 201, and COYA 206 between 2024 and 2026.
  • Raised $11.1 million in January 2026, including $10 million from Dr. Reddy's, to scale up manufacturing.

What Makes Coya Stand Out in the Crowd

Coya focuses on therapies that target immune system regulation, a key factor in many diseases. Its business model relies on partnerships and licensing, not direct product sales. The company uses outside labs and manufacturers to keep operations lean and flexible.

Five Things You Need to Know

  • Collaboration revenue was $7.9 million in 2025, up 119% from 2024.
  • Operating expenses rose to $30.5 million in 2025, up 46.6% from 2024.
  • Net loss reached $21.2 million in 2025, widening from $14.9 million in 2024.
  • Cash and cash equivalents were $46.8 million as of December 31, 2025.

Bottom Line

Coya has evolved by expanding its drug pipeline and forming strategic partnerships. The company remains focused on immune therapies, with all revenue from collaborations, not product sales.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

8

CEO

Arun Swaminathan, PhD

Website

www.coyatherapeutics.com

Headquarters

Houston, TX 77057, US

COYA Financials

Key Financial Metrics (TTM)

Gross Margin

99.79%

Operating Margin

-277.02%

Net Income Margin

-266.11%

Return on Equity

-57.26%

Return on Capital

-47.10%

Return on Assets

-39.66%

Earnings Yield

-23.64%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$107.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

23.46M

Volume

56.98K

Avg. Volume

209.86K

Financials (TTM)

Gross Profit

$7.92M

Operating Income

-$21.99M

EBITDA

-$21.10M

Operating Cash Flow

-$14.12M

Capital Expenditure

-$3.00

Free Cash Flow

-$14.12M

Cash & ST Invst.

$50.72M

Total Debt

$0.00

Coya Therapeutics Performance Analysis

Coya Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 6,002,206N/A
20242024-12-31USD 3,554,061-40.8%
20252025-12-31USD 7,945,753123.6%
Coya Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-36.6%
Q32025-09-302078.4%
Q42025-12-3111.1%
Q12026-03-31-93.7%
Coya Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.23143.5%
20232023-12-31USD -0.79-36.2%
20242024-12-31USD -0.9824.3%
20252025-12-31USD -1.2729.9%
Coya Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3018.2%
Q32025-09-3063.9%
Q42025-12-31-161.5%
Q12026-03-315.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$251.15K

-2.6%

Gross Profit

$248.34K

+105.0%

Gross Margin

98.88%

N/A

Market Cap

$107.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$13.43M

N/A

Employees

8

N/A

Net Income

-$7.21M

+1.4%

EBITDA

-$7.20M

+1.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$50.72M

+42.8%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-39.66%

N/A

Return on Invested Capital

-44.23%

N/A

Free Cash Flow

-$6.21M

-119.5%

Operating Cash Flow

-$6.21M

-119.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PLRXPliant Therapeutics, Inc.
$1.05-0.95%
CLNNClene Inc.
$5.28-1.12%
CNTXContext Therapeutics Inc.
$0.51+1.94%
ORMPOramed Pharmaceuticals Inc.
$4.32+0.47%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$129.74+0.13%
TTDThe Trade Desk
$14.17-0.20%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$8.27+0.08%
NAMIJinxin Technology
$5.12+0.76%

Questions About COYA

What is the current price of Coya Therapeutics?

Coya Therapeutics is trading at $4.70 per share.

What is the 52-week range for Coya Therapeutics?

Over the past 52 weeks, Coya Therapeutics has traded between $3.71 and $7.75.

How much debt does Coya Therapeutics have?

As of the most recent reporting period, Coya Therapeutics reported total debt of $0.00.

How much cash does Coya Therapeutics have on hand?

Coya Therapeutics reported $50.72M in cash and cash equivalents in its most recent financial results.

What is Coya Therapeutics’s dividend yield?

Coya Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services